Zeria Pharmaceutical Co., Ltd. (TYO:4559)
Japan · Delayed Price · Currency is JPY 2,084.00
+13.00 (0.63%)
Jul 17, 2025, 3:30 PM JST
Zeria Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 87,311 | 75,725 | 68,383 | 59,532 | 55,442 | Upgrade | |
Revenue Growth (YoY) | 15.30% | 10.74% | 14.87% | 7.38% | -8.25% | Upgrade |
Cost of Revenue | 23,351 | 20,224 | 18,895 | 17,384 | 15,807 | Upgrade |
Gross Profit | 63,960 | 55,501 | 49,488 | 42,148 | 39,635 | Upgrade |
Selling, General & Admin | 41,806 | 36,834 | 32,646 | 30,993 | 30,781 | Upgrade |
Research & Development | 4,106 | 3,726 | 3,456 | 4,789 | 5,411 | Upgrade |
Operating Expenses | 51,762 | 45,879 | 40,473 | 35,782 | 36,192 | Upgrade |
Operating Income | 12,198 | 9,622 | 9,015 | 6,366 | 3,443 | Upgrade |
Interest Expense | -452 | -457 | -337 | -315 | -238 | Upgrade |
Interest & Investment Income | 623 | 438 | 296 | 209 | 255 | Upgrade |
Earnings From Equity Investments | -276 | -76 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 634 | -1,182 | -1,416 | -329 | -322 | Upgrade |
Other Non Operating Income (Expenses) | 113 | 167 | 19 | 2 | 35 | Upgrade |
EBT Excluding Unusual Items | 12,840 | 8,512 | 7,577 | 5,933 | 3,173 | Upgrade |
Gain (Loss) on Sale of Investments | -208 | 499 | 19 | 14 | 375 | Upgrade |
Gain (Loss) on Sale of Assets | 2 | 2 | 1 | 3 | - | Upgrade |
Asset Writedown | -15 | -482 | -6 | -4 | -36 | Upgrade |
Other Unusual Items | -2 | 977 | -321 | -226 | 409 | Upgrade |
Pretax Income | 12,617 | 9,508 | 7,270 | 5,720 | 3,921 | Upgrade |
Income Tax Expense | 2,650 | 1,813 | 1,065 | 1,746 | 791 | Upgrade |
Earnings From Continuing Operations | 9,967 | 7,695 | 6,205 | 3,974 | 3,130 | Upgrade |
Minority Interest in Earnings | -31 | 36 | -10 | -13 | -11 | Upgrade |
Net Income | 9,936 | 7,731 | 6,195 | 3,961 | 3,119 | Upgrade |
Net Income to Common | 9,936 | 7,731 | 6,195 | 3,961 | 3,119 | Upgrade |
Net Income Growth | 28.52% | 24.79% | 56.40% | 27.00% | 6.63% | Upgrade |
Shares Outstanding (Basic) | 44 | 44 | 44 | 45 | 46 | Upgrade |
Shares Outstanding (Diluted) | 44 | 44 | 44 | 45 | 46 | Upgrade |
Shares Change (YoY) | -0.00% | -0.21% | -2.14% | -2.02% | -1.38% | Upgrade |
EPS (Basic) | 225.41 | 175.39 | 140.24 | 87.75 | 67.70 | Upgrade |
EPS (Diluted) | 225.41 | 175.39 | 140.24 | 87.75 | 67.70 | Upgrade |
EPS Growth | 28.52% | 25.06% | 59.82% | 29.62% | 8.12% | Upgrade |
Free Cash Flow | 11,493 | 9,283 | 10,757 | 7,886 | 6,160 | Upgrade |
Free Cash Flow Per Share | 260.73 | 210.59 | 243.52 | 174.71 | 133.70 | Upgrade |
Dividend Per Share | 47.000 | 44.000 | 40.000 | 35.000 | 34.000 | Upgrade |
Dividend Growth | 6.82% | 10.00% | 14.29% | 2.94% | - | Upgrade |
Gross Margin | 73.26% | 73.29% | 72.37% | 70.80% | 71.49% | Upgrade |
Operating Margin | 13.97% | 12.71% | 13.18% | 10.69% | 6.21% | Upgrade |
Profit Margin | 11.38% | 10.21% | 9.06% | 6.65% | 5.63% | Upgrade |
Free Cash Flow Margin | 13.16% | 12.26% | 15.73% | 13.25% | 11.11% | Upgrade |
EBITDA | 19,752 | 17,177 | 15,163 | 11,765 | 7,878 | Upgrade |
EBITDA Margin | 22.62% | 22.68% | 22.17% | 19.76% | 14.21% | Upgrade |
D&A For EBITDA | 7,554 | 7,555 | 6,148 | 5,399 | 4,435 | Upgrade |
EBIT | 12,198 | 9,622 | 9,015 | 6,366 | 3,443 | Upgrade |
EBIT Margin | 13.97% | 12.71% | 13.18% | 10.69% | 6.21% | Upgrade |
Effective Tax Rate | 21.00% | 19.07% | 14.65% | 30.52% | 20.17% | Upgrade |
Advertising Expenses | 5,650 | 5,290 | 4,379 | 3,546 | 5,348 | Upgrade |
Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.